Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 983

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 983
---
writing discounts and commissions and the payment of other offering expenses
payable by the Company of approximately $510,000.

On February 1, 2024 and April 9, 2024, the Company
issued 8,326 shares and 8,326 shares of common stock, respectively upon the exercise of 8,326 and 8,326 January 2024 Pre-Funded Warrants,
respectively, resulting in aggregate proceeds to the Company of $9,990.

On April 1, 2024, the Company entered into an
Amendment to the Debt Exchange Agreement with Trevally, LLC (“Trevally”), which amends the original agreement with Trevally
(executed in January 2023). Pursuant to the Amendment, Trevally agreed to return 2,000 shares of the Company’s common stock, initially
issued to Trevally in January 2023 as advance consideration for agreeing to complete the synthesis of research materials for the Company.
Trevally returned the previously issued shares for no consideration on April 3, 2024. Trevally delivered the completed research materials
to the Company on July 1, 2024.

On July 12, 2024, the Company entered into an
At-the-Market Issuance Sales Agreement (the “ATM Agreement”) with WallachBeth Capital LLC as sales agent, to sell shares
of common stock having an aggregate offering price of up to $1,253,603 from time to time, through an “at the market offering”
program (the “ATM Offering”). The offer and sale of shares of common stock from the ATM Offering were made pursuant to the
Company’s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained
therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended four times to increase the maximum
aggregate offering price under the ATM Agreement. From July 19, 2024 to August 1, 2024, the Company sold a total of 135,568 shares in
the ATM Offering for gross proceeds of $1,994,583.

On July 22, 2024 and July 26, 2024, the Company
converted 1,291 and 1,032 shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into 8,000 shares and 6,667
shares of common stock